Saturday 17 October 2026
Export GUTS’s income statement to Excel — free account
Fractyl Health, Inc.
GUTS Healthcare Biotechnology
Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023. In the quarter to June 2026, revenue fell 57.1%, EPS grew 71.9%, free cash flow grew 25.3% and total debt rose 1.54%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.55
2.61
−62.74%
Follow GUTS
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | — |
Altman Z-Score |
— | — | 0.45 | — |
P/S ratio |
— | 2,701.07 | 11,573.74 | — |
Altman Z″-Score (non-manufacturers) |
— | (18.05) | (14.81) | — |
P/FCF ratio |
— | 0.00 | 0.00 | — |
P/Operating CF |
— | (30.58) | (63.19) | — |
P/B ratio |
— | 0.00 | 37.87 | — |
Price to Tangible BV |
— | 0.00 | 37.87 | — |
EV/Sales |
— | 2,881.30 | 11,172.65 | — |
EV/EBITDA |
— | 0.00 | 0.00 | — |
EV/Operating CF |
— | (8.07) | (15.86) | — |
EV/FCF |
— | (8.01) | (15.44) | — |
Quick Ratio |
6.74 | 3.00 | 3.41 | 4.45 |
Current Ratio |
7.06 | 3.19 | 3.63 | 4.78 |
Net Debt/EBITDA |
0.64 | (0.43) | 0.40 | 0.53 |
Debt/Assets |
29.14% | 72.37% | 27.91% | 25.19% |
Debt/Equity |
(0.07) | (0.17) | 1.06 | 3.23 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.73 | 0.45 | 0.95 | 0.64 |
Capex/Depreciation |
(0.12) | (1.26) | (2.61) | (0.49) |
| 0.00% | 32.65% | 46.32% | (744.17%) | |
| 0.00% | (137.45%) | (74.55%) | (122.85%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(142.53%) | (377.84%) | (124.97%) | (196.71%) |
Average Days of Receivables |
— | 66.92 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 31,698.33% | 75,775.27% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 10,700.83% | 24,841.94% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 3,580.00% | 15,511.83% | 0.00% |
Graham Net Nets |
— | (1.13) | (0.01) | — |
Graham Number |
— | 368.74 | 0.00 | — |
Earnings Yield |
— | (25.34%) | (6.19%) | — |
Free Cash Flow Yield |
— | (13.32%) | (6.25%) | — |
Revenue per Share |
0.00 | 0.06 | 0.00 | 0.00 |
Operating CF per Share |
(23.24) | (20.58) | (1.50) | (1.19) |
Capex per Share |
(0.03) | (0.17) | (0.04) | (0.01) |
Free Cash Flow per Share |
(23.27) | (20.75) | (1.55) | (1.20) |
Cash per Share |
24.76 | 16.11 | 1.55 | 1.08 |
Shareholders Equity per Share |
(126.79) | (156.20) | 0.65 | 0.12 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(126.79) | (156.20) | 0.65 | 0.12 |
Free Cash Flow |
(46.30) | (43.18) | (67.29) | (90.88) |
Working Capital |
44.32 | 24.46 | 51.99 | 69.25 |
Capital Expenditures |
(0.06) | (0.36) | (1.76) | (0.56) |
Net Current Asset Value |
(261.65) | (365.63) | (7.89) | (24.37) |
EV/EBIT |
— | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 2.99 | 18.98 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | — |
| Other line items | ||||
Depreciation/Fixed assets |
1.39 | 0.58 | 0.23 | 0.47 |
Cash ROIC |
24.99% | 18.27% | (53.38%) | (74.75%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | — |
Accounts Payable Turnover |
— | 0.10 | 0.03 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.68 | — |
Average Days of Payables |
0.00 | 2,621.36 | 23,652.00 | 0.00 |
Days of Inventory on Hand |
— | 346.04 | 532.90 | — |
Average Payables |
— | 0.77 | 1.90 | 2.41 |
Average Inventory |
— | — | 0.07 | — |
Average Assets |
— | 68.58 | 92.14 | 114.74 |
Average Common Equity |
— | (288.69) | (148.32) | 18.94 |
Columns are period end dates